Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

 
• By Jessica Merrill

The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.

Competitive Advantage in a Business Competition Environment; 3d Render
Lilly sees a competitive advantage for tirzepatide • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas